Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area cell cycle c myc'

Search results for: 'research area cell cycle c myc'

9 Items

per page
  1. SU5416
    A3847 SU5416
    Target: VEGFR
    Summary: VEGF receptor inhibitor and AHR agonist
      insoluble in EtOH; insoluble in H2O; ≥11.9 mg/mL
  2. SB1317
    A3794 SB1317
    Summary: CDK,JAK and FLT inhibitor
      insoluble in H2O; ≥44.87 mg/mL
  3. Amuvatinib (MP-470, HPK 56)
    A4237 Amuvatinib (MP-470, HPK 56)
    Summary: Tyrosine kinase inhibitor
      ≥22.4 mg/mL
  4. TG101209
    A4145 TG101209
    Summary: JAK2/3 inhibitor
      ≥25.5 mg/mL
  5. Cabozantinib (XL184, BMS-907351)
    A2977 Cabozantinib (XL184, BMS-907351)
    Summary: VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor
      ≥25.08 mg/mL
  6. Silvestrol
    A3818 Silvestrol
    Summary: Antineoplastic
      Soluble in DMSO
  7. Tandutinib (MLN518)
    B1526 Tandutinib (MLN518)
    Summary: FLT3 inhibitor,potent and selective
      ≥17.85 mg/mL
  8. Tandutinib (MLN518) HCl
    B7853 Tandutinib (MLN518) HCl
    Summary: FLT3 inhibitor,potent and selective
      ≥59.9 mg/mL
  9. Lestaurtinib
    A4513 Lestaurtinib
     1 Citation
    Summary: JAK2/FLT3/TrkA inhibitor
      Soluble in DMSO

9 Items

per page